Floatz logo

Cyclophosphamide

Primary Biliary Cholangitis

Eli Lilly and CompanySmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

16 Active assets in the Primary Biliary Cholangitis cohort.

Asset / SponsorPhaseRating
Saroglitazar
Zydus Therapeutics Inc.
Phase 3BB
ABATACEPT RECOMBINANT
Eli Lilly and Company
Phase 4BB
cs0159
Cascade Pharmaceuticals, Inc
Phase 3BB
Mbx-8025
Gilead Sciences
Phase 3BB
Obeticholic Acid
Intercept Pharmaceuticals
Phase 3BB

View all 33 →

Same molecule, other indications

Cyclophosphamide is also rated in:

adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
mycosis fungoidesDormant
BBB
Indicative ·
78 / 100
View asset →
B-cell childhood acute lymphoblastic leukemiaDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →